Drugs in Development
By: Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, Patrick Marcellin, MD, Norah Terrault, MD, MPH
|
Expert clinicians discuss key findings on hepatitis B virus therapy from the 43rd Annual Meeting of the European Association for the Study of the Liver
Date Posted: 7/3/2008
|
By: Robert S. Brown, Jr., MD, MPH, Tram T. Tran, MD
|
Tram T. Tran, MD, and Robert S. Brown, Jr., MD, MPH, discuss new agents for the treatment of chronic hepatitis B and how they might fit in the treatment landscape.
Date Posted: 6/24/2008
|
By: Daniel Shouval, MD
|
Daniel Shouval, MD, provides an update on the latest management strategies for patients with chronic hepatitis B.
Date Posted: 6/18/2008
|
 |
Review the new therapies for hepatitis B, and the clinical issues facing these candidates.
File Format: Microsoft PowerPoint (.ppt) | File Size: 1,188 KB
Date Posted: 5/19/2008
|
 |
Download and review key data selected by Daniel Shouval, MD on clinical HBV data that was presented at the 2008 EASL meeting in Milan. Use the slides in your own presentations!
File Format: Microsoft PowerPoint (.ppt) | File Size: 948 KB
Date Posted: 5/9/2008
|
By: Raymond T. Chung, MD
|
Watch and listen as Raymond T. Chung, MD, reviews key data and updates on hepatitis B management presented at the 2007 Boston liver disease meeting.
Date Posted: 1/7/2008
|
 |
Review the most clinically relevant HBV data from the 2007 Boston meeting and download the slides for use in your own presentations.
File Format: Microsoft PowerPoint (.ppt) | File Size: 650 KB
Date Posted: 11/28/2007
|
|
Tenofovir therapy demonstrates robust efficacy and is well tolerated among HBeAg-negative chronic hepatitis B cohort
Date Posted: 11/7/2007
|
|
Tenofovir therapy demonstrates robust efficacy and is well tolerated among HBeAg-positive chronic hepatitis B cohort
Date Posted: 11/7/2007
|
|
Complete virologic suppression achieved in adefovir-resistant chronic hepatitis B patients following tenofovir therapy.
Date Posted: 11/6/2007
|
|
Featured Content
Review a module and Interactive Case Challenge and use the new HBV DNA monitoring tool.
Join our experts as they review treatment options for patients with nonresponse to HCV therapy.
Expert faculty members review the most important advances in hepatitis and its mgmt in 2008.
|
|